<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A Phase II study of GM-CSF with intermediate-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> was conducted in patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an "S" phase increase of 2.55x at 48 hr </plain></SENT>
<SENT sid="3" pm="."><plain>Unexpected <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> was noted </plain></SENT>
<SENT sid="4" pm="."><plain>This regimen cannot be recommended for this elderly population of patients </plain></SENT>
</text></document>